Janus kinase inhibitors are effective in atopic keratoconjunctivitis treatment and not only in managing dupilumab-induced ocular adverse events
Atopic keratoconjunctivitis (AKC) is a potentially sight-threatening form of ocular surface inflammation, affecting up to 30% of patients with atopic dermatitis. This study highlights for the first time the potential value of Janus kinase inhibitors in the treatment of AKC and not only in managing dupilumab-induced ocular adverse events.
Authors
- Benjamin M. Jacob (ORCID: https://orcid.org/0000-0003-1119-064X)
- F. Tétart (ORCID: https://orcid.org/0000-0003-2383-3753)
- M. Muraine (ORCID: https://orcid.org/0000-0001-5908-1827)
- J. Gueudry (ORCID: https://orcid.org/0000-0002-8592-3810)
- Yasmine Bendoukha
Institutions
- Université de Rouen Normandie (FR)
Publication Details
- Journal
- British Journal of Dermatology
- Published
- 2025-10-26
- DOI
- https://doi.org/10.1093/bjd/ljaf424
- Primary Topic
- Dermatology and Skin Diseases
- Type
- article
- Field-Weighted Citation Impact
- 0.00